News from edison pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Sep 03, 2014, 00:01 ET Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome

 Edison Pharmaceuticals today announced results of a recently completed phase 2 placebo-controlled trial in pediatric patients. Rett syndrome...


Jun 09, 2014, 00:01 ET FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Leigh Syndrome

 Edison Pharmaceuticals today announced that the FDA has granted Orphan Drug status to vatiquinone for the treatment of Leigh syndrome....


Mar 10, 2014, 00:01 ET Edison Announces Initiation of EPI-743 Phase 2B/3 Leigh Syndrome Clinical Trial With Dainippon Sumitomo Pharma Co. Ltd. in Japan

Edison Pharmaceuticals today announced the initiation of a phase 2B/3 study entitled, "A Phase 2B/3 Open-label Study of EPI-743 in Children with...


Feb 04, 2014, 00:01 ET FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Friedreich's Ataxia

Edison Pharmaceuticals today announced that the US Food and Drug Administration has granted Orphan Status to vatiquinone for the treatment of...


Jan 31, 2014, 01:30 ET Edison Pharmaceuticals, Inc. enters into strategic alliance with Dainippon Sumitomo Pharma Co., Ltd.

 Edison Pharmaceuticals today announced that it has entered into a strategic alliance valued up to $4.295 billion with Dainippon Sumitomo...


Mar 28, 2013, 08:55 ET Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs

 Edison Pharmaceuticals today announced that it has entered into a research/development and commercialization...


Feb 19, 2013, 00:01 ET Edison Pharmaceuticals & Bambino Gesu Children's Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial

 Edison Pharmaceuticals today announced the initiation of a phase 2 clinical trial entitled, "Double-Blind, Placebo-Controlled Clinical Trial...


Jan 07, 2013, 00:01 ET Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Friedreich's Ataxia Clinical Trial

Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, "Safety and Efficacy Study of EPI-743 on Visual Function in...


Nov 26, 2012, 11:20 ET Edison Pharmaceuticals Closes $20M Series F Financing

Edison Pharmaceuticals, Inc. announced today that it has closed a Series F Preferred Financing, raising $20M. Mitsui & Co. Global Investment,...


Sep 13, 2011, 11:56 ET Edison Pharmaceuticals, Inc. Closes Financing

Edison Pharmaceuticals, Inc. announced today that it has closed a Series E Preferred Financing. Capital raised will fund US and European approval...


Jun 10, 2011, 17:38 ET Edison Pharmaceuticals Announces Results of EPI-A0001 Phase 2A Double Blind Placebo Controlled 28-Day Clinical Trial in the Mitochondrial Disease- Friedreich's Ataxia

Edison Pharmaceuticals, Inc. announced today preliminary results obtained on a 28-day phase 2A clinical trial in Friedreich's ataxia. While the...


Jun 08, 2011, 22:37 ET Edison Pharmaceuticals annonce l'octroi de la désignation de medicament orphelin EPI-743 de la FDA

- Cette désignation couvre les maladies en rapport avec un trouble de la chaîne respiratoire de la mitochondrie Edison...


Jun 08, 2011, 18:11 ET Edison Pharmaceuticals élargit l'accès à EPI-743 pour les maladies mitochondriales

- La FDA autorise l'utilisation d'un nouveau médicament expérimental pour les cas menaçant le pronostic vital Edison...


Jun 08, 2011, 17:14 ET Edison Pharmaceuticals sorgt für erweiterten Zugang zu EPI-743 für mitochondriale Erkrankungen

- FDA genehmigt Anwendung von Medikament in klinischer Testphase (Investigational New Drug) bei lebensbedrohlichen Befunden Edison...


Jun 08, 2011, 15:56 ET Edison Pharmaceuticals meldet Erteilung des Orphan-Drug-Status für EPI-743 durch FDA

- Orphan-Drug-Ausweisung gilt für ererbte mitochondriale Atmungskettenerkrankungen Edison Pharmaceuticals, Inc. gab heute bekannt, dass...


Jun 08, 2011, 15:50 ET Edison Pharmaceuticals vai disponibilizar maior acesso ao EPI-743 para doença mitocondrial

A Edison Pharmaceuticals, Inc. anunciou hoje que a U.S. Food and Drug Administration (FDA – Administração de Medicamentos e...


Jun 08, 2011, 13:26 ET Edison Pharmaceuticals Anuncia que FDA Otorgó a EPI-743 la Designación de Medicamento Huérfano

Edison Pharmaceuticals, Inc. anunció hoy que la United States Food and Drug Administration otorgó la designación de medicamento...


Jun 08, 2011, 13:18 ET Edison Pharmaceuticals proporciona un acceso ampliado a EPI-743 para la enfermedad mitocondrial

- La FDA ha permitido el uso de un nuevo fármaco investigacional para las enfermedades que suponen una amenaza para la vida Edison...


Jun 08, 2011, 13:12 ET La FDA concede la designación de fármaco huérfano a EPI-743, de Edison Pharmaceuticals

- La designación cubre las enfermedades de la cadena respiratoria heredadas de la mitocondria Edison Pharmaceuticals, Inc. ha anunciado...


Jun 08, 2011, 12:13 ET Edison Pharmaceuticals ofrecerá un acceso ampliado al EPI-743 para la enfermedad mitocondrial

Edison Pharmaceuticals, Inc. anunció hoy que la Administración de Drogas y Alimentos (FDA, por sus siglas en inglés) autorizó...


Jun 08, 2011, 09:36 ET O FDA fornece a designação de medicamento órfão ao EPI-743 da Edison Pharmaceuticals

Edison Pharmaceuticals, Inc. anunciou hoje que a Administração dos Alimentos e Medicamentos dos Estados Unidos concedeu a...


Jun 08, 2011, 03:01 ET Edison Pharmaceuticals to Provide Expanded Access to EPI-743 for Mitochondrial Disease

Edison Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has allowed an Expanded Access program to provide...


Jun 08, 2011, 00:01 ET Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation

Edison Pharmaceuticals, Inc. announced today the United States Food and Drug Administration has granted orphan drug designation to EPI-743 for...


Jan 05, 2010, 12:29 ET Edison Pharmaceuticals Licenses Drug from Centocor for Rare Diseases

Edison Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has licensed CNTO-530, a clinical-stage...


Jul 15, 2008, 01:00 ET Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development

SAN JOSE, Calif., July 15 /PRNewswire/ -- Edison Pharmaceuticals, Inc., a privately held biotechnology company located in San Jose, CA,...